BioTech Annecto

biotechannecto.com

BioTech Annecto is a social networking organization, whose aim is to bring together entrepreneurs, investors, scientists, attorneys, journalists and other professionals in the biotechnology sector: pharmaceutical, healthcare and biomedical, cosmetics, and environment. Launched February 2009 in Montreal (Quebec, Canada), BioTech Annecto (previously known as BioTech Montreal) is inviting people, one Tuesday every month, from the Montreal biotechnology community to meet at trendy locations around town. Members come from the business world, from public agencies as well as academic institutions. This allows regular communication and exchanges between industry, the public sector and academia.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ENTERS STRATEGIC PARTNERSHIP WITH OXGENE™ TO ADDRESS SUPPLY BOTTLENECKS IN GENE THERAPY DEVELOPMENT & MANUFACTURING

FUJIFILM Diosynth Biotechnologies | April 23, 2020

news image

FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies. This partnership will enable FDB to deliver gene therapy products to clients with an approximate 25% le...

Read More

Medical

MELINTA THERAPEUTICS PARTNERS WITH BARDA TO ADVANCE TWO FDA-APPROVED ANTIBIOTICS FOR USE IN PEDIATRIC PATIENTS

Businesswire | July 11, 2023

news image

Melinta Therapeutics, LLC a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin) and VABOMERE® (meropenem and vaborbactam), for use in pediatrics. In addition, Melinta and BARDA will partner on the development of BAXDELA® against biothreat pathogens...

Read More

Cell and Gene Therapy, Industrial Impact

GENSCRIPT PROBIO ENTERS INTO STRATEGIC PARTNERSHIP WITH RVAC MEDICINES

GenScript ProBio | February 24, 2023

news image

GenScript ProBio, a renowned Contract Development and Manufacturing Organization (CDMO), has recently entered a strategic partnership agreement with RVAC Medicines Pte. Ltd., a biotech company specializing in the development and commercialization of mRNA vaccines and therapeutics. The collaboration is aimed at manufacturing GMP-grade plasmid DNA (pDNA) for the RVM-V001 mRNA COVID-19 vaccine candidate, as well as supporting future therapeutic pipelines. GenScript ProBio will offe...

Read More

Medical

ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS

PR Newswire | October 12, 2023

news image

Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases. With t...

Read More
news image

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ENTERS STRATEGIC PARTNERSHIP WITH OXGENE™ TO ADDRESS SUPPLY BOTTLENECKS IN GENE THERAPY DEVELOPMENT & MANUFACTURING

FUJIFILM Diosynth Biotechnologies | April 23, 2020

FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies. This partnership will enable FDB to deliver gene therapy products to clients with an approximate 25% le...

Read More
news image

Medical

MELINTA THERAPEUTICS PARTNERS WITH BARDA TO ADVANCE TWO FDA-APPROVED ANTIBIOTICS FOR USE IN PEDIATRIC PATIENTS

Businesswire | July 11, 2023

Melinta Therapeutics, LLC a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin) and VABOMERE® (meropenem and vaborbactam), for use in pediatrics. In addition, Melinta and BARDA will partner on the development of BAXDELA® against biothreat pathogens...

Read More
news image

Cell and Gene Therapy, Industrial Impact

GENSCRIPT PROBIO ENTERS INTO STRATEGIC PARTNERSHIP WITH RVAC MEDICINES

GenScript ProBio | February 24, 2023

GenScript ProBio, a renowned Contract Development and Manufacturing Organization (CDMO), has recently entered a strategic partnership agreement with RVAC Medicines Pte. Ltd., a biotech company specializing in the development and commercialization of mRNA vaccines and therapeutics. The collaboration is aimed at manufacturing GMP-grade plasmid DNA (pDNA) for the RVM-V001 mRNA COVID-19 vaccine candidate, as well as supporting future therapeutic pipelines. GenScript ProBio will offe...

Read More
news image

Medical

ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS

PR Newswire | October 12, 2023

Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases. With t...

Read More